Home › Trials › NCT06866782

Registry collecting data on advanced prostate cancer imaging

European Registry of Next Generation Imaging in Advanced Prostate Cancer

Fundacio Puigvert · NCT06866782

This study is collecting information on how advanced imaging techniques for prostate cancer can help doctors make better treatment decisions and improve patient outcomes.

Quick facts

Study typeObservational
Enrollment600 (estimated)
Ages18 Years and up
SexMale
SponsorFundacio Puigvert (other)
Locations24 sites (Leuven and 23 other locations)
Trial IDNCT06866782 on ClinicalTrials.gov

What this trial studies

This registry collects real-world data on advanced prostate cancer imaging to evaluate the effectiveness of next-generation imaging (NGI) techniques, such as PET/CT and whole-body MRI, compared to conventional imaging methods. It aims to identify the proportion of patients who benefit from NGI at baseline and assess how imaging influences treatment decisions in clinical practice. The study will also stratify metastatic prostate cancer patients based on imaging results and evaluate survival outcomes related to the imaging pathways used. Data will be gathered from medical records and analyzed to improve understanding of imaging's impact on patient outcomes.

Who should consider this trial

Good fit: Ideal candidates are adult men aged 18 or older with histologically confirmed prostate cancer who require imaging to assess potential metastases.

Not a fit: Patients participating in other studies requiring NGI for metastatic assessment or those with significant comorbid conditions may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance the accuracy of metastatic prostate cancer detection and improve treatment decision-making for patients.

How similar studies have performed: Other studies have shown promising results with next-generation imaging approaches in cancer detection, indicating potential for success in this registry.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Adult male patients (≥18 years with no upper age limit).
2. Histologically proven prostate cancer.
3. Patients who require imaging exploration (conventional, Next-Generation Imaging (NGI), or their combination) at high risk for harbouring metastatic deposits at the hormone-sensitive stage, either at the diagnostic workout of a "naïve" patient or at biochemical relapse/progression after local treatment.
4. Patients who authorize their participation in the study by signing a written informed consent form (ICF).

Exclusion Criteria:

1. Patients participating in other interventional or non-interventional study which requires NGI as a triage test for metastatic assessment.
2. Patients with evidence of any other clinically significant disease or condition which in the opinion of the investigator discourages their participation in the study.
3. Patients who will not be able to complete the study.

Where this trial is running

Leuven and 23 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Prostate Cancer, Advanced Prostate Cancer, Metastatic Prostate Cancer, prostate cancer, advanced prostate cancer, new generation imaging, conventional imaging, Magnetic Resonance Imaging

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.